» Articles » PMID: 27990018

Chlamydial Protease-like Activity Factor Mediated Protection Against C. Trachomatis in Guinea Pigs

Overview
Publisher Wiley
Date 2016 Dec 20
PMID 27990018
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

We have comprehensively demonstrated using the mouse model that intranasal immunization with recombinant chlamydial protease-like activity factor (rCPAF) leads to a significant reduction in bacterial burden, genital tract pathology and preserves fertility following intravaginal genital chlamydial challenge. In the present report, we evaluated the protective efficacy of rCPAF immunization in guinea pigs, a second animal model for genital chlamydial infection. Using a vaccination strategy similar to the mouse model, we intranasally immunized female guinea pigs with rCPAF plus CpG deoxynucleotides (CpG; as an adjuvant), and challenged intravaginally with C. trachomatis serovar D (CT-D). Immunization with rCPAF/CpG significantly reduced vaginal CT-D shedding and induced resolution of infection by day 24, compared with day 33 in CpG alone treated and challenged animals. Immunization induced robust anti-rCPAF serum IgG 2 weeks following the last immunization, and was sustained at a high-level 4 weeks post challenge. Upregulation of antigen-specific IFN-γ gene expression was observed in rCPAF/CpG-vaccinated splenocytes. Importantly, a significant reduction in inflammation in the genital tissue in rCPAF/CpG-immunized guinea pigs compared with CpG-immunized animals was observed. Taken together, this study provides evidence of the protective efficacy of rCPAF as a vaccine candidate in a second animal model of genital chlamydial infection.

Citing Articles

vaccines for genital infections: where are we and how far is there to go?.

de la Maza L, Darville T, Pal S Expert Rev Vaccines. 2021; 20(4):421-435.

PMID: 33682583 PMC: 8934038. DOI: 10.1080/14760584.2021.1899817.


Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Li W, Gudipaty P, Li C, Henderson K, Ramsey K, Murthy A Immunol Cell Biol. 2018; 97(1):85-91.

PMID: 30051926 PMC: 6338504. DOI: 10.1111/imcb.12192.


The effect of infectious dose on humoral and cellular immune responses in Chlamydophila caviae primary ocular infection.

Filipovic A, Ghasemian E, Inic-Kanada A, Lukic I, Stein E, Marinkovic E PLoS One. 2017; 12(7):e0180551.

PMID: 28678871 PMC: 5498042. DOI: 10.1371/journal.pone.0180551.

References
1.
Conrad T, Yang Z, Ojcius D, Zhong G . A path forward for the chlamydial virulence factor CPAF. Microbes Infect. 2013; 15(14-15):1026-32. PMC: 4320975. DOI: 10.1016/j.micinf.2013.09.008. View

2.
Cotter T, Ramsey K, Miranpuri G, Poulsen C, Byrne G . Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun. 1997; 65(6):2145-52. PMC: 175296. DOI: 10.1128/iai.65.6.2145-2152.1997. View

3.
Hafner L . Pathogenesis of fallopian tube damage caused by Chlamydia trachomatis infections. Contraception. 2015; 92(2):108-15. DOI: 10.1016/j.contraception.2015.01.004. View

4.
Frey A, Di Canzio J, Zurakowski D . A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1999; 221(1-2):35-41. DOI: 10.1016/s0022-1759(98)00170-7. View

5.
Bavoil P, Byrne G . Analysis of CPAF mutants: new functions, new questions (the ins and outs of a chlamydial protease). Pathog Dis. 2014; 71(3):287-91. PMC: 5914542. DOI: 10.1111/2049-632X.12194. View